Arcutis Biotherapeutics, Inc. (ARQT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:41AM EDT. Market open.
| Previous close | 7.96 |
| Open | 7.90 |
| Bid | 7.73 x 400 |
| Ask | 7.91 x 400 |
| Day's range | 7.70 - 7.90 |
| 52-week range | 1.76 - 13.17 |
| Volume | |
| Avg. volume | 2,983,449 |
| Market cap | 907.59M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.00 |
ZacksHas Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
ZacksWall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksAvidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
© 2024 Yahoo. All rights reserved.